LRRK2 and Parkinson disease: In vitro studies showed that pathogenic mutations such as G2019S within the kinase domain or R1441G at the guanosine triphosphatase (GTPase) domain enhance LRRK2 activity,17 thus supporting a kinase gain of function in PD.18